Table 1. Baseline characteristics of patients enrolled in the First BEAT and NO16966 trials.
| First BEAT trial (n=1914) | NO16966 | ||
|---|---|---|---|
| FOLFOX or XELOX + placebo (n=701) | FOLFOX or XELOX + bevacizumab (n=699) | ||
| Sex (%) | |||
| Male | 58 | 56 | 60 |
| Female | 42 | 44 | 40 |
| Age | |||
| Median | 59 | 60 (FOLFOX/placebo) | 60 (FOLFOX/bev) |
| 61 (XELOX/placebo) | 61 (XELOX/bev) | ||
| ECOG PS (%) | |||
| 0 | 65 | 60 | 58 |
| 1 | 34 | 40 | 41 |
| Primary tumour site (%) | |||
| Colon | 62 | 66 | 66 |
| Rectum | 27 | 26 | 26 |
| Colon and rectum | 11 | 8 | 9 |
| Previous adjuvant therapy (%) | |||
| Yes | 38 | 25 | 23 |
| No | 62 | 75 | 77 |
| Number of metastatic sites (%) | |||
| 1 | 61 | 42 | 41 |
| >1 | 39 | 57 | 59 |
Abbreviations: BEAT=bevacizumab expanded access trial; ECOG=Eastern Cooperative Oncology Group; FOLFOX4=5-FU and oxaliplatin; XELOX=capecitabine plus oxaliplatin.